Research on immunotherapy in the MYC+RAS HDI mouse model of liver cancer

Primary liver cancer (PLC) presents significant challenges for immunotherapy due to its marked heterogeneity. In 2022, we reported the generation of 25 primary liver cancer mouse models through in situ gene editing of hepatocytes, and conducted multi-omics analyses to establish their representation of the major histopathological types of human primary liver cancer. Using techniques such as mass cytometry (CyTOF), we described the immune landscape of eight representative primary liver cancer mouse models, categorizing them into four immune types. Additionally, we discovered that RAS gene-induced primary liver cancer mouse models exhibited higher levels of immunogenicity and responsiveness to immunotherapy. Single-cell analysis and TCR-T cell killing revealed tumor-specific TCRs in RAS tumors.